The cannabigerol market is surging worldwide, with China posting a 9.0% compound annual growth rate (CAGR) through 2036, followed by the United States at 8.5% and Canada at 8.0%. Fact.MR data shows rapid expansion across major pharmaceutical hubs, driven by regulatory shifts and infrastructure investments.
China Drives 9.0% CAGR as Pharmaceutical Infrastructure Expands
China leads the market with a 9.0% CAGR through 2036, fueled by rapid expansion of pharmaceutical infrastructure and rising domestic demand for high‑quality cannabinoid compounds. Fact.MR attributes this growth to government support for modernizing healthcare and to the emergence of advanced research capabilities in Beijing, Shanghai and Guangzhou.
Major pharmaceutical firms are building comprehensive R&D networks to meet the needs of a growing provider base and to supply export markets, positioning China as a primary driver of global CBG demand.
USA Posts 8.5% CAGR Amid Regulatory Advances
The United States records an 8.5% CAGR, driven by increasing regulatory accessibility and growing pharmaceutical awareness. Fact.MR notes that expanding research markets in New York, California and Massachusetts are creating demand for high‑quality CBG as companies seek domestic sources to reduce import reliance.
Strong pharma infrastructure and cost‑competitive production are supporting this expansion, positioning the U.S. as a key supplier of cannabinoid therapies.
Canada Maintains 8.0% CAGR with Research Leadership
Canada maintains an 8.0% CAGR through 2036, leveraging its advanced pharmaceutical technology sector and robust research centers. The country’s focus on product quality and regulatory compliance drives demand for premium CBG compounds that integrate seamlessly with existing healthcare platforms.
Germany Leads Europe at 7.8% CAGR
Germany posts a 7.8% CAGR, reflecting strong pharmaceutical demand in Berlin, Munich and other key regions. Fact.MR highlights that cost‑effective cannabinoid solutions are attracting investment in new research facilities and equipment modernization.
UK Emphasizes Advanced Pharmaceutical Development
The United Kingdom grows at 7.6% CAGR, supported by a sophisticated healthcare ecosystem and a focus on technology‑integrated CBG products. Fact.MR data shows that 45% of UK applications target pharmaceuticals, 35% nutraceuticals and 20% cosmetics, underscoring a diversified market.
South Korea Shows Steady Market Growth
South Korea records a steady 7.0% CAGR, driven by demand for high‑quality, precision‑engineered CBG that aligns with strict operational standards. The market prioritizes reliability and long‑term performance, with local manufacturers meeting Korean healthcare regulations.
Japan Emphasizes Precision and Integration Excellence
Japan’s market expands at 6.8% CAGR, reflecting a strong preference for natural hemp‑derived CBG (90%) while allowing limited synthetic production (10%). Advanced extraction algorithms and strict quality standards shape demand for premium CBG that integrates with Japanese pharmaceutical equipment.
Europe Market Split by Country
Europe’s overall market is projected to reach a substantial size, with Germany leading at USD 200 million in 2026, followed by the UK (USD 150 million), France (USD 120 million), Italy (USD 100 million), Spain (USD 80 million) and the Rest of Europe (USD 240 million). These figures, sourced from Fact.MR, illustrate how individual country performance varies within a cohesive regional growth trend.
